(VIANEWS) - Tandem Diabetes Care (TNDM), Steven Madden, Ltd. (SHOO), Omnicell (OMCL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Tandem Diabetes Care (TNDM)
38.4% sales growth and 6.08% return on equity
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.
Tandem Diabetes Care's sales growth this year is anticipated to be 37.2% and 19.9% for next year.
Year-on-year quarterly revenue growth grew by 45.3%, now sitting on 660.87M for the twelve trailing months.
Volume
Today's last reported volume for Tandem Diabetes Care is 723187 which is 2.8% below its average volume of 744036.
Tandem Diabetes Care's sales growth for the next quarter is 38.4%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.08%.
Volatility
Tandem Diabetes Care's last day, last week, and last month's current volatility was 1.42%, 2.37%, and 1.86%, respectively.
Tandem Diabetes Care's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.46% (day), 3.62% (last week), and 3.10% (last month), respectively.
Tandem Diabetes Care's Stock Yearly Top and Bottom Value
Tandem Diabetes Care's stock is valued at $130.65 at 15:22 EST, under its 52-week high of $142.03 and way higher than its 52-week low of $76.19.
Tandem Diabetes Care's Moving Average
Tandem Diabetes Care's value is above its 50-day moving average of $127.27 and way higher than its 200-day moving average of $106.17.2. Steven Madden, Ltd. (SHOO)
21% sales growth and 19.07% return on equity
Steven Madden, Ltd.
Steven Madden, Ltd.'s sales growth this year is expected to be 50.5% and 11.4% for next year.
Year-on-year quarterly revenue growth grew by 52.4%, now sitting on 1.64B for the twelve trailing months.
Volume
Today's last reported volume for Steven Madden, Ltd. is 1304380 which is 80.24% above its average volume of 723675.
Steven Madden, Ltd.'s sales growth for the next quarter is 21%. The company's growth estimates for the ongoing quarter and the next is 137% and 36.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.07%.
Volatility
Steven Madden, Ltd.'s last day, last week, and last month's current volatility was 0.08%, 3.20%, and 1.61%, respectively.
Steven Madden, Ltd.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.34% (day), 3.89% (last week), and 2.85% (last month), respectively.
Steven Madden, Ltd.'s Stock Yearly Top and Bottom Value
Steven Madden, Ltd.'s stock is valued at $49.77 at 15:22 EST, under its 52-week high of $51.40 and way above its 52-week low of $27.29.
Steven Madden, Ltd.'s Moving Average
Steven Madden, Ltd.'s worth is way higher than its 50-day moving average of $43.12 and way above its 200-day moving average of $42.01.3. Omnicell (OMCL)
19.8% sales growth and 7.91% return on equity
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.
Omnicell's sales growth this year is expected to be 26.4% and 14.3% for next year.
Year-on-year quarterly revenue growth grew by 38.7%, now sitting on 1.07B for the twelve trailing months.
Volume
Today's last reported volume for Omnicell is 236818 which is 5% below its average volume of 249286.
Omnicell's sales growth for the next quarter is 19.8%. The company's growth estimates for the ongoing quarter and the next is 4.4% and 6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.91%.
Volatility
Omnicell's last day, last week, and last month's current volatility was 0.01%, 0.96%, and 1.24%, respectively.
Omnicell's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.86% (day), 4.03% (last week), and 3.07% (last month), respectively.
Omnicell's Stock Yearly Top and Bottom Value
Omnicell's stock is valued at $177.32 at 15:22 EST, below its 52-week high of $182.73 and way above its 52-week low of $93.39.
Omnicell's Moving Average
Omnicell's worth is above its 50-day moving average of $162.23 and way higher than its 200-day moving average of $150.78.Previous days news about Omnicell(OMCL)
- Notable omnicell insider trades $960k in company stock. According to Benzinga on Wednesday, 3 November, "What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Dan S Johnston exercised options to purchase 5,358 Omnicell shares for $0 on November 2. ", "Dan S Johnston, EVP And Chief Legal & Admin at Omnicell (NASDAQ:OMCL), made a large buy and sell of company shares on November 2, according to a new SEC filing."
4. Regeneron Pharmaceuticals (REGN)
18.3% sales growth and 51.32% return on equity
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Regeneron Pharmaceuticals's sales growth this year is anticipated to be 56.3% and a negative 10.8% for next year.
Year-on-year quarterly revenue growth grew by 163.2%, now sitting on 12.2B for the twelve trailing months.
Volume
Today's last reported volume for Regeneron Pharmaceuticals is 1756860 which is 112.22% above its average volume of 827818.
Regeneron Pharmaceuticals's sales growth for the next quarter is 18.3%. The company's growth estimates for the ongoing quarter and the next is 7.7% and 8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.32%.
Volatility
Regeneron Pharmaceuticals's last day, last week, and last month's current volatility was 0.69%, 1.06%, and 1.25%, respectively.
Regeneron Pharmaceuticals's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.58% (day), 3.21% (last week), and 2.42% (last month), respectively.
Regeneron Pharmaceuticals's Stock Yearly Top and Bottom Value
Regeneron Pharmaceuticals's stock is valued at $611.54 at 15:22 EST, way under its 52-week high of $686.62 and way above its 52-week low of $441.00.
Regeneron Pharmaceuticals's Moving Average
Regeneron Pharmaceuticals's value is above its 50-day moving average of $595.40 and above its 200-day moving average of $573.21.Previous days news about Regeneron Pharmaceuticals(REGN)
- According to CNBC on Wednesday, 3 November, "Toyota Motors, Regeneron Pharmaceuticals and Kellogg are among the companies set to post quarterly updates. "
- According to Bloomberg Quint on Friday, 5 November, "Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems."
- According to Bloomberg Quint on Friday, 5 November, "Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems."
5. Qualys (QLYS)
12% sales growth and 16.97% return on equity
Qualys, Inc. provides cloud-based information technology (IT), security, and compliance solutions in the United States and internationally.
Qualys's sales growth this year is anticipated to be 12.1% and 11.7% for next year.
Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 384.33M for the twelve trailing months.
Volume
Today's last reported volume for Qualys is 748947 which is 152.8% above its average volume of 296252.
Qualys's sales growth is a negative 0% for the ongoing quarter and 12% for the next. The company's growth estimates for the ongoing quarter and the next is 2.6% and 2.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.97%.
Volatility
Qualys's last day, last week, and last month's current volatility was 1.48%, 2.30%, and 1.42%, respectively.
Qualys's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.75% (day), 4.29% (last week), and 3.01% (last month), respectively.
Qualys's Stock Yearly Top and Bottom Value
Qualys's stock is valued at $135.04 at 15:22 EST, under its 52-week high of $148.84 and way higher than its 52-week low of $87.75.
Qualys's Moving Average
Qualys's worth is way above its 50-day moving average of $116.91 and way higher than its 200-day moving average of $107.90.6. Atlas Air Worldwide Holdings (AAWW)
10.2% sales growth and 20.56% return on equity
Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services.
Atlas Air Worldwide Holdings's sales growth this year is anticipated to be 22.3% and a negative 1% for next year.
Year-on-year quarterly revenue growth grew by 20%, now sitting on 3.59B for the twelve trailing months.
Volume
Today's last reported volume for Atlas Air Worldwide Holdings is 708831 which is 41.01% above its average volume of 502663.
Atlas Air Worldwide Holdings's sales growth for the next quarter is 10.2%. The company's growth estimates for the present quarter and the next is a negative 2.1% and negative -5.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.56%.
Volatility
Atlas Air Worldwide Holdings's last day, last week, and last month's current volatility was 1.35%, 2.05%, and 1.68%, respectively.
Atlas Air Worldwide Holdings's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.23% (day), 3.82% (last week), and 3.13% (last month), respectively.
Atlas Air Worldwide Holdings's Stock Yearly Top and Bottom Value
Atlas Air Worldwide Holdings's stock is valued at $89.50 at 15:22 EST, below its 52-week high of $91.18 and way higher than its 52-week low of $50.22.
Atlas Air Worldwide Holdings's Moving Average
Atlas Air Worldwide Holdings's worth is way above its 50-day moving average of $80.83 and way higher than its 200-day moving average of $73.53.Previous days news about Atlas Air Worldwide Holdings(AAWW)
- Atlas air worldwide holdings inc. Q3 adjusted earnings beat estimates. According to Business Insider on Wednesday, 3 November, "Excluding items, Atlas Air Worldwide Holdings Inc. reported adjusted earnings of $145.45 million or $4.88 per share for the period."
- According to Bloomberg Quint on Wednesday, 3 November, "Freight and leasing company Atlas Air Worldwide Holdings Inc., which bought the rights to the last four 747-8s in January, plans to take delivery of the hulking cargo haulers between May and October of next year, Chief Executive Officer John Dietrich said during an earnings call Wednesday."
7. Texas Instruments (TXN)
8.3% sales growth and 71.55% return on equity
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide.
Texas Instruments's sales growth this year is anticipated to be 23.9% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 41.4%, now sitting on 16.76B for the twelve trailing months.
Volume
Today's last reported volume for Texas Instruments is 4328750 which is 22.69% above its average volume of 3528120.
Texas Instruments's sales growth for the next quarter is 8.3%. The company's growth estimates for the current quarter and the next is 40.7% and 16.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 71.55%.
Volatility
Texas Instruments's last day, last week, and last month's current volatility was 1.01%, 0.46%, and 1.12%, respectively.
Texas Instruments's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.49% (day), 1.51% (last week), and 1.79% (last month), respectively.
Texas Instruments's Stock Yearly Top and Bottom Value
Texas Instruments's stock is valued at $193.40 at 15:22 EST, below its 52-week high of $202.26 and way higher than its 52-week low of $151.02.
Texas Instruments's Moving Average
Texas Instruments's worth is under its 50-day moving average of $193.97 and higher than its 200-day moving average of $189.41.Previous days news about Texas Instruments(TXN)
- According to Bloomberg Quint on Thursday, 4 November, "Consider Texas Instruments Inc. The semiconductor stalwart sells the basic building-block chips that go into productsin nearly every sector of the economy from autos and industrials to consumer electronics. ", "On top of providing a lower-than-expected forecast for the December quarter, Texas Instruments said clients were now being "more selective" in asking for rush delivery for chips. "
- According to Bloomberg Quint on Thursday, 4 November, "Chipmaker Texas Instruments Inc., a bellwether for the industry because of its tremendous reach, recently revealed a forecast that suggested the surge in electronic components is already beginning to slow."
8. Owens & Minor (OMI)
6.6% sales growth and 37.37% return on equity
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally.
Owens & Minor's sales growth this year is anticipated to be 15.5% and a negative 0.6% for next year.
Year-on-year quarterly revenue growth grew by 37.7%, now sitting on 9.37B for the twelve trailing months.
Volume
Today's last reported volume for Owens & Minor is 895974 which is 16.93% above its average volume of 766210.
Owens & Minor's sales growth for the next quarter is 6.6%. The company's growth estimates for the current quarter and the next is a negative 30.9% and negative -32.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 37.37%.
Volatility
Owens & Minor's last day, last week, and last month's current volatility was 22.30%, 5.78%, and 2.48%, respectively.
Owens & Minor's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 15.73% (day), 5.30% (last week), and 3.68% (last month), respectively.
Owens & Minor's Stock Yearly Top and Bottom Value
Owens & Minor's stock is valued at $45.81 at 15:22 EST, under its 52-week high of $49.16 and way above its 52-week low of $21.76.